— Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.
— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.
— SRPT shares ended Wednesday’s regular trading session down 1.14%.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
Lyft (LYFT) expects average ride volumes to improve through Q1 2021
Shares of Lyft Inc. (NASDAQ: LYFT) were up 8% in afternoon hours on Wednesday. The stock has gained 53% over the past 12 months and 25% since the beginning of
With new strategy in place, Target looks poised to tap growing online demand
Department store chain Target Corp. (NYSE: TGT), which has been thriving on the pandemic-driven shopping boom since early last year, maintained its strong performance during the holiday season and entered
Infographic: Dollar Tree’s (DLTR) performance in Q4
Dollar Tree (NYSE: DLTR) reported fourth-quarter financial results before the opening bell on Wednesday. The discount store reported a 7% increase in Q4 net sales to $6.7 billion. The company
